Inhaled therapy shows promise for lung metastases

NCT ID NCT01590069

First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 28 times

Summary

This study tests an inhaled form of a protein called interleukin-2 (IL-2) to treat cancers that have spread to the lungs, such as melanoma, kidney cancer, and sarcoma. The goal is to find the safest dose and see if it can shrink tumors. About 70 adults with advanced cancer and lung metastases are taking part. The treatment is breathed in through a nebulizer, aiming to boost the immune system directly in the lungs while reducing side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IV CUTANEOUS MELANOMA AJCC V6 AND V7 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.